'Ares, HPS Line Up $3 Billion Debt for Carlyle's Baxter Unit Bid' - Bloomberg
$ARES
$BAX
$CG
Investment Managers
Finance
Medical/Dental Instruments
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/12/2024 | $42.00 | Equal Weight | Wells Fargo | |
| 9/12/2024 | $156.00 | Equal Weight | Wells Fargo | |
| 8/27/2024 | $55.00 | Buy | Redburn Atlantic | |
| 8/27/2024 | $140.00 | Neutral | Redburn Atlantic | |
| 8/6/2024 | $46.00 → $44.00 | Overweight → Neutral | JP Morgan | |
| 7/15/2024 | $39.00 → $30.00 | Equal-Weight → Underweight | Morgan Stanley | |
| 6/13/2024 | $176.00 → $132.00 | Buy → Hold | Deutsche Bank | |
| 5/30/2024 | $36.00 | Neutral | Goldman |
Ares Management Corp. (NYSE:ARES) and HPS Investment Partners are spearheading a $3 billion credit facility to finance Carlyle Group Inc.’s (NASDAQ:CG) potential acquisition of Baxter International Inc.’s (NYSE:BAX) kidney-care division. This debt package includes a $2.5 billion unitranche loan and a $450 million revolver. Oaktree Capital Management is also involved in the financing, and smaller lenders may participate after signing. Also Read: Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System. The financing terms suggest an interest rate five percentage points above the Secured Overnight Financing Rate, placing the division Vantive’s leverage at 4.2
https://www.bloomberg.com/news/articles/2024-07-23/ares-hps-line-up-3-billion-debt-for-carlyle-s-baxter-unit-bid?sref=y3YMCJ4e
Directors Robert Langer and Stephen Berenson will also retire from the Board.
Wells Fargo initiated coverage of Carlyle Group with a rating of Equal Weight and set a new price target of $42.00
Wells Fargo initiated coverage of Ares Management with a rating of Equal Weight and set a new price target of $156.00
Redburn Atlantic initiated coverage of Carlyle Group with a rating of Buy and set a new price target of $55.00
4 - Ares Management Corp (0001176948) (Reporting)
4 - Ares Management Corp (0001176948) (Reporting)
4 - Ares Management Corp (0001176948) (Reporting)
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)
SC 13G/A - Ares Management Corp (0001176948) (Subject)
SC 13G/A - Ares Management Corp (0001176948) (Subject)
144 - Ares Management Corp (0001176948) (Subject)
144 - Ares Management Corp (0001176948) (Subject)
10-Q - BAXTER INTERNATIONAL INC (0000010456) (Filer)
4 - Ares Management Corp (0001176948) (Reporting)
4 - Ares Management Corp (0001176948) (Issuer)
4 - Ares Management Corp (0001176948) (Issuer)
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock. This dividend represents the new quarterly dividend rate for Baxter in anticipation of the divestiture of its Kidney Care business segment to Carlyle (NASDAQ:CG), which is expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. Over its 93-year history, Baxter has co
Baxter third-quarter 2024 sales totaled $3.85 billion1 Third-quarter total Baxter U.S. GAAP2 diluted earnings per share (EPS) were $0.271; adjusted total Baxter diluted EPS were $0.801, exceeding the company's previously issued guidance Third-quarter sales from continuing operations of $2.70 billion increased 4% on both a reported and constant currency basis3, reflecting growth across all segments4 Third-quarter U.S. GAAP diluted EPS from continuing operations were $0.12; adjusted continuing operations EPS were $0.49 Baxter continues to make significant progress restoring production at its North Cove facility following the unprecedented impact of Hurricane Helene in western North C
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its third quarter ended September 30, 2024. Justin Plouffe, CGBD's Chief Executive Officer said, "We delivered consistent performance in the third quarter of 2024, capitalizing on increased new deal activity and the strength of our existing portfolio companies. With another strong quarter of originations, we benefited from access to the broader Carlyle Global Credit Platform, as we supplemented our core cash flow strategy with differentiated deal flow and specialty lending
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 9:10 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, June 3, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been oper
MCLEAN, Va., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for government healthcare agencies and the priority populations they serve, announced that Harish Nanda, the company's Chief Technology Officer, has been named a 2024 NVTC Tech100 Tech Executive honoree by the Northern Virginia Technology Council (NVTC). NVTC is one of the nation's largest technology councils, with a mission to establish the Northern Virginia region as a major global technology center. NVTC also recognized Acentra Health among Tech100 companies for driving innovation and supporting the region's economic growth.
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 11:00 a.m. Greenwich Mean Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Monday, May 19, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've bee
Michael Smith and Mitch Goldstein Appointed as Co-Chairmen of Board of Directors Ares Capital Corporation ("Ares Capital") (NASDAQ:ARCC) announced today that James ("Jim") R. Miller was appointed as Co-President to serve alongside current Co-President, Kort Schnabel. Concurrently, Ares Capital's Board of Directors was expanded by one member. Mitchell ("Mitch") Goldstein joined Ares Capital's Board of Directors, and Mitch Goldstein and Michael L. Smith have been appointed to serve as Co-Chairmen of Ares Capital's Board of Directors. Michael Arougheti will cease to serve as Chairman of Ares Capital's Board of Directors but will continue to serve as a Director. Kipp deVeer will continue in hi
Transaction Reinforces AIR's Presence in Europe and Enhances its Capabilities for Integration of Advanced Robotics into Automated Systems Vivian Farrell Promoted to President of Automated Industrial Robotics, Ireland Automated Industrial Robotics Inc. ("AIR" or the "Company") today announced the acquisition of Robotics & Drives ("RDS"), an Ireland-based industrial automation company focused on delivering innovative solutions through robotics technology. The transaction further reinforces AIR's presence in Europe, strengthens the Company's ability to integrate robotics solutions into its automated systems and adds to the product portfolio. The transaction was funded primarily by an additio
London, UK and New York, USA, September 10, 2024 - Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ:CG), today announced the appointment of Robert (Bob) DeBenedetto as Managing Director – Clinical Co-Development. Bob brings to Abingworth over 30 years of experience in the life sciences industry and will be working on Clinical Co-Development deals and execution with new and existing Abingworth portfolio companies. He will be based in Abingworth's Menlo Park, CA, USA office. Prior to joining Abingworth, Bob was the Founder, President and CEO of SFJ Pharmaceuticals Inc. (CA, USA), an Abingworth portfolio company, where he